Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
Position statement from the Indian Society of Gastroenterology, Cardiological Society of India, Indian Academy of Neurology and Vascular Society of India on gastrointestinal bleeding and endoscopic procedures in patients on antiplatelet and/or anticoagulant therapy.
СтатьяConsensus StatementНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arora Anil, Kumar Ashish, Anand Anil C, Kumar Ajay, Yadav Ajay, Bhagwat Ajit, Mullasari Ajit S, Satwik Ambarish, Saraya Anoop, Mehta Ashwani, Roy Debabrata, Reddy Duvvur Nageshwar, Makharia Govind, Murthy Jagarapudi M K, Roy Jayanta, Sawhney Jitendra P S, Prasad Kameshwar, Goenka Mahesh, Philip Mathew, Umaiorubahan Meenakshisundaram, Sinha Nakul, Mohanan Padinhare P, Sylaja Padmavathy N, Ramakrishna Pinjala, Kerkar Prafulla, Rai Praveer, Kochhar Rakesh, Yadav Rakesh, Nijhawan Sandeep, Sinha Saroj K, Hastak Shirish M, Viswanathan Sidharth, Ghoshal Uday C, Madathipat Unnikrishnan, Thakore Vijay, Dhir Vinay, Saraswat Vivek A, Nabi Zaheer
Аннотация
Antiplatelet and/or anticoagulant agents (collectively known as antithrombotic agents) are used to reduce the risk of thromboembolic events in patients with conditions such as atrial fibrillation, acute coronary syndrome, recurrent stroke prevention, deep vein thrombosis, hypercoagulable states and endoprostheses. Antithrombotic-associated gastrointestinal (GI) bleeding is an increasing burden due to the growing population of advanced age with multiple comorbidities and the expanding indications for the use of antiplatelet agents and anticoagulants. GI bleeding in antithrombotic users is associated with an increase in short-term and long-term mortality. In addition, in recent decades, there has been an exponential increase in the use of diagnostic and therapeutic GI endoscopic procedures. Since endoscopic procedures hold an inherent risk of bleeding that depends on the type of endoscopy and patients' comorbidities, in patients already on antithrombotic therapies, the risk of procedure-related bleeding is further increased. Interrupting or modifying doses of these agents prior to any invasive procedures put these patients at increased risk of thromboembolic events. Although many international GI societies have published guidelines for the management of antithrombotic agents during an event of GI bleeding and during urgent and elective endoscopic procedures, no Indian guidelines exist that cater to Indian gastroenterologists and their patients. In this regard, the Indian Society of Gastroenterology (ISG), in association with the Cardiological Society of India (CSI), Indian Academy of Neurology (IAN) and Vascular Society of India (VSI), have developed a "Guidance Document" for the management of antithrombotic agents during an event of GI bleeding and during urgent and elective endoscopic procedures.